BioSpace News Archive

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that Chief Financial Officer Matt Harbaugh will participate in the Canaccord Genuity 42nd Annual Growth Conference in Boston on Thursday, August 11, 2022.

Labcorp today announced that its Board of Directors has authorized the Company to pursue a spin-off of the Company’s wholly owned Clinical Development business to Labcorp shareholders through a tax-free transaction.

Vicinitas Therapeutics today launched with $65 million in Series A financing.

Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2022, at 8:30 a.m. ET to discuss second quarter 2022 results and provide a general business update.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022.

Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced the addition of Liz Bhatt, MS, MBA, as Chief Operating Officer, and Ran Xiao as Vice President of Finance and Business.

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading participation and top spot, for the third year in a row, as a Distinguished Founder’s Circle Sponsor for the 2022 American Society of Transplant Surgeons (ASTS) Summer Winter Symposium.

Many of the world’s leading neurosurgeons gathered to share experiences on new technologies that are making minimally invasive surgical approaches and associated improved patient outcomes more achievable in neurosurgery.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2022 investor call on Thursday, August 4, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.

OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2022 financial results after the close of the U.S. financial markets on Thursday, August 11th , 2022.